JPRN-jRCT2080222550未知1 期
A Phase 1 study of KRN23 in Subjects with X-linked Hypophosphatemic Rickets/Osteomalacia
Kyowa Hakko Kirin Co., Ltd.0 个研究点目标入组 15 人开始时间: 2014年7月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients with XLH
排除标准
- •1. Have an active infection or chronic inflammatory disease
- •2. Have uncontrolled hypertension
- •3. Have uncontrolled diabetes mellitus
- •4. History of known immunodeficiency
- •5. Use of a pharmacologic vitamin D, or its metabolite or its analogs within 21 days prior to screening and after screening
- •6. Use of phosphate, calcium preparation, calcimimetics, aluminum hydroxide antacids, thiazide diuretic, acetazolamide, or phosphate, calcium, and/or vitamin D-containing supplements within 10 days prior to screening and after screening
- •7. Pregnant or lactating females, women who are possibly pregnant or patients who have no intention of utilizing adequate contraception
研究者
相似试验
进行中（未招募）
1 期
An Investigational Immunotherapy Study of NKTR-214 and Nivolumab vs Nivolumab alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaEUCTR2018-001423-40-FRBristol-Myers Squibb International Corporation1,020
进行中（未招募）
1 期
A study of NKTR-214 combined with Nivolumab vs Nivolumab alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaEUCTR2018-001423-40-Outside-EU/EEABristol-Myers Squibb International Corporation
进行中（未招募）
1 期
A study of NKTR-214 combined with Nivolumab vs Nivolumab alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaEUCTR2018-001423-40-FIBristol-Myers Squibb International Corporation1,020
进行中（未招募）
1 期
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab alone in Participants With Previously Untreated Inoperable or Metastatic Melanomantreated unresectable or metastatic melanomaMedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2018-001423-40-GRBristol-Myers Squibb International Corporation1,009
进行中（未招募）
1 期
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Aone inParticipants With Previously Untreated Inoperable or Metastatic MelanomaEUCTR2018-001423-40-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO1,020